Soleno Therapeutics, Inc. (SLNO) Stock
Soleno Therapeutics, Inc.
Company profile
In Q3 2025 (the quarter ended September 30, 2025) revenue was $66.02 million. In Q3 2025 it reported net income of $26.01 million, against a net loss of $76.62 million a year earlier.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss widened from $38.99 million in fiscal year 2023 to $175.85 million in fiscal year 2024.
- It reported no revenue in fiscal year 2024 or in the 4 fiscal years before; it spent $78.57 million on research and development.
Figures from company filings; latest fiscal year ended December 31, 2024.
Largest shareholders
- Fidelity Management & Research Co. LLC11.21%
- Wellington Trust Co., NA8.57%
- Wellington Management Co. LLP8.57%
- BlackRock Advisors LLC6.75%
- SSgA Funds Management, Inc.5.19%
Share of the company, as of May 19, 2026
In the news
- Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law FirmPRNewsWire ·
- 5 Small Drug Stocks to Buy as Industry Recovery Picks Up
- Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)?
- Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
What companies are similar to Soleno Therapeutics?
Listed companies of a similar size in the same industry (obesity treatment pharmaceuticals) include Rhythm Pharmaceuticals, Inc. (RYTM), Structure Therapeutics Inc. (GPCR), BioAge Labs, Inc. (BIOA), Aardvark Therapeutics, Inc. (AARD).
Has Soleno Therapeutics made a profit in recent years?
Net income by fiscal year: FY2020, a loss of $24.64 million; FY2021, a loss of $30.91 million; FY2022, a loss of $24.07 million; FY2023, a loss of $38.99 million; FY2024, a loss of $175.85 million. It reported a net loss in each of these 5 years.
How much does Soleno Therapeutics spend on research and development?
Research and development by fiscal year: FY2020, $23.19 million; FY2021, $21.45 million; FY2022, $15.27 million; FY2023, $25.19 million; FY2024, $78.57 million.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Soleno Therapeutics, Inc. (SLNO)”, data as of May 19, 2026, https://dataporium.tech/stocks/SLNO